Avadel Pharma (AVDL) Misses Q2 EPS by 47c

Avadel Pharma (NASDAQ: AVDL) reported Q2 EPS of ($0.83), $0.47 worse than the analyst estimate of ($0.36).

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Jana Partners urges Cooper Companies to replace CEO and explore asset sales
• Deutsche Bank Reiterates Buy Rating on Redcare Pharmacy NV (RDC:GR)